<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK547883" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK547883/" /><meta name="ncbi_pagename" content="Canakinumab - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Canakinumab - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Canakinumab" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/04/20" /><meta name="citation_pmid" content="31643219" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK547883/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Canakinumab" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/04/20" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK547883/" /><meta name="description" content="Canakinumab is a monoclonal antibody to interleukin-1 (IL-1) beta which is used in the therapy of juvenile idiopathic arthritis and other autoinflammatory conditions. Canakinumab is a relatively new biologic agent, has had limited clinical use, but has yet to be linked to cases of clinically apparent, acute liver injury." /><meta name="og:title" content="Canakinumab" /><meta name="og:type" content="book" /><meta name="og:description" content="Canakinumab is a monoclonal antibody to interleukin-1 (IL-1) beta which is used in the therapy of juvenile idiopathic arthritis and other autoinflammatory conditions. Canakinumab is a relatively new biologic agent, has had limited clinical use, but has yet to be linked to cases of clinically apparent, acute liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK547883/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Canakinumab/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK547883/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D18F0046640110000000005080171.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK547883_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK547883_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/CalciumChannelBlocke/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Candesartan/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK547883_"><span class="title" itemprop="name">Canakinumab</span></h1><p class="small">Last Update: <span itemprop="dateModified">April 20, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Canakinumab.OVERVIEW"><h2 id="_Canakinumab_OVERVIEW_">OVERVIEW</h2><div id="Canakinumab.Introduction"><h3>Introduction</h3><p>Canakinumab is a monoclonal antibody to interleukin-1 (IL-1) beta which is used in the therapy of juvenile idiopathic arthritis and other autoinflammatory conditions. Canakinumab is a relatively new biologic agent, has had limited clinical use, but has yet to be linked to cases of clinically apparent, acute liver injury.</p></div><div id="Canakinumab.Background"><h3>Background</h3><p>Canakinumab (kan&#x0201d; a kin&#x02019; ue mab) is a human monoclonal antibody to IL-1 beta. The antibody reactivity is specific for IL-1 beta with no cross reactivity to other members of the IL-1 family or other cytokines. IL-1 is a key proinflammatory cytokine that medicates local and systemic inflammatory reactions and can induce fever, pain sensitization, bone and cartilage destruction and acute phase plasma protein reactions. In several controlled trials and open label studies, canakinumab has been shown to improve symptoms and laboratory abnormalities associated with juvenile idiopathic arthritis (formerly juvenile rheumatoid arthritis or Still disease) and several rare autoinflammatory conditions such as cryopyrin associated periodic syndrome (CAPS), Schnitzler syndrome and familial Mediterranean fever. Canakinumab was approved for use in periodic fever syndromes in the United States in 2009 and indications were later expanded to include juvenile idiopathic arthritis, Familial Mediterranean Fever, hyperimmunoglobulin D syndrome, and tumor necrosis factor receptor associated periodic syndrome (TRAPS). Canakinumab is considered a disease modifying antirheumatic drug (DMARD), and improves signs and symptoms of disease and decreases cartilage and tissue destruction. For juvenile idiopathic arthritis, canakinumab is given by subcutaneous injection every 8 weeks in a dose of 4 mg/kg (for patients weighing &#x0003e;7.5 kg) with a maximum dose of 300 mg. Lower doses are used in cryopyrin associated periodic syndromes. The most frequent side effects are local skin reactions, gastrointestinal upset, diarrhea, vertigo and possibly an increased incidence of bacterial infections. Uncommon but potentially severe adverse events include severe infections, immunosuppression, macrophage activation syndrome and hypersensitivity reactions.</p></div><div id="Canakinumab.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In large registration trials, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations occurred in 1% to 4% of patients taking canakinumab, a rate similar to or minimally above that in placebo recipients. Serum aminotransferase levels are often raised in children with juvenile idiopathic arthritis and adult onset Still disease, and instances of improvement in serum enzyme elevations with initiation of canakinumab therapy have been reported. There have been no published reports of clinically apparent liver injury with jaundice attributed to canakinumab. On the other hand, in large case series and registries, adverse events of hepatobiliary disorders and hepatitis have been reported. Some of these may have been instances of macrophage activation syndrome arising during therapy, a severe complication of inflammatory arthritides that can be accompanied by hepatic injury. Canakinumab has had limited clinical use, but hepatic injury with jaundice due to canakinumab must be rare, if it occurs. In addition, canakinumab has not been linked to cases of reactivation of hepatitis B or exacerbation of chronic hepatitis C which can occur with other cytokines and anticytokines.</p><p>Likelihood score: E* (unproven but suspected rare cause of clinically apparent liver injury).</p></div><div id="Canakinumab.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>Canakinumab is a monoclonal antibody and has minimal hepatic metabolism. The mechanism by which it causes serum enzyme elevations during therapy is unknown, but may be the result of its effects on the immune system or on the IL-1 pathways which are important in inflammation and cell damage.</p></div><div id="Canakinumab.Outcome_and_Management"><h3>Outcome and Management</h3><p>Agents that block the proinflammatory pathways of IL-1 and IL-6 share similar activity against autoinflammatory diseases and have little evidence for hepatotoxicity. However, there is no reason to suspect that there may be cross sensitivity to hepatic injury between canakinumab and other IL-1 antagonists such as anakinra and rilonacept or other immune modulating biologic agents such as tocilizumab or tumor necrosis factor antagonists.</p><p>Drug Class: <a href="/books/n/livertox/AntirheumaticAgents/">Antirheumatic Agents</a></p><p>Other Drugs in the Subclass, <a href="/books/n/livertox/InterleukinRcptAntag/">Interleukin Receptor Antagonists</a>: <a href="/books/n/livertox/Anakinra/">Anakinra</a>, <a href="/books/n/livertox/Rilonacept/">Rilonacept</a>, <a href="/books/n/livertox/Sarilumab/">Sarilumab</a>, <a href="/books/n/livertox/Tocilizumab/">Tocilizumab</a></p></div></div><div id="Canakinumab.PRODUCT_INFORMATION"><h2 id="_Canakinumab_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Canakinumab &#x02013; Ilaris&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antirheumatic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Canakinumab" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Canakinumab.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Canakinumab_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Canakinumab.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547883/table/Canakinumab.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Canakinumab.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Canakinumab.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Canakinumab.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Canakinumab.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Canakinumab.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Canakinumab.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Canakinumab</td><td headers="hd_h_Canakinumab.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">914613-48-2</td><td headers="hd_h_Canakinumab.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Monoclonal Antibody</td><td headers="hd_h_Canakinumab.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not Available</td></tr></tbody></table></div></div></div><div id="Canakinumab.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Canakinumab_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 20 April 2020</p><p>Abbreviations: IL1, interleukin 1; CAPS, cryopyrin-associated periodic syndrome; DMARD, disease modifying anti-rheumatic drug; TRAPS, tumor necrosis factor receptor associated periodic syndrome.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Canakinumab.REF.zimmerman.1999">Zimmerman HJ. Drugs used to treat rheumatic and musculospastic disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 517-53.<div><i>(Expert review of hepatotoxicity published in 1999 before the availability of canakinumab and the IL-1 blockers).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.krensky.2018">Krensky AM, Azzi JR, Hafler DA. Immunosuppressants and tolerogens. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 637-53.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.bywaters.1971.121">Bywaters EG. Still's disease in the adult. <span><span class="ref-journal">Ann Rheum Dis. </span>1971;<span class="ref-vol">30</span>:121–33.</span> [<a href="/pmc/articles/PMC1005739/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1005739</span></a>] [<a href="/pubmed/5315135" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5315135</span></a>]<div><i>(Clinical description of 14 patients with adult onset Still disease seen at a single referral center in the UK over a 25 year period; all woman, ages 17 to 35 years, presenting with urticarial, macular rash, high fevers, fatigue and arthritis, high ESR but no rheumatoid factor, the majority ultimately recovering completely without residual arthritis or problems).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.andr_s.2003.192">Andr&#x000e8;s E, Kurtz JE, Perrin AE, Pflumio F, Ruellan A, Goichot B, Dufour P, et al.  Retrospective monocentric study of 17 patients with adult Still's disease, with special focus on liver abnormalities. <span><span class="ref-journal">Hepatogastroenterology. </span>2003;<span class="ref-vol">50</span>:192–5.</span> [<a href="/pubmed/12630021" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12630021</span></a>]<div><i>(Among 17 patients with adult onset Still disease seen at a single French referral center, mean age was 27 years and 76% had "moderate liver dysfunction" with hepatomegaly in 47%, bilirubin 0.6-1.3 mg/dL and ALT 32-252 U/L, all eventually having a "complete recovery").</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.efthimiou.2006.144">Efthimiou P, Georgy S. Pathogenesis and management of adult-onset Still's disease. <span><span class="ref-journal">Semin Arthritis Rheum. </span>2006;<span class="ref-vol">36</span>:144–52.</span> [<a href="/pubmed/16949136" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16949136</span></a>]<div><i>(Adult onset Still disease is a rare, systemic inflammatory disorder of unknown cause characterized by fever, distinctive skin rash, arthritis and multiorgan involvement).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.zhu.2009.284">Zhu G, Liu G, Liu Y, Xie Q, Shi G. Liver abnormalities in adult onset Still's disease: a retrospective study of 77 Chinese patients. <span><span class="ref-journal">J Clin Rheumatol. </span>2009;<span class="ref-vol">15</span>:284–8.</span> [<a href="/pubmed/19734733" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19734733</span></a>]<div><i>(Retrospective analysis of clinical features of 77 patients with adult onset Still disease presenting at a single referral center in China reported hepatomegaly in 12%, ALT or AST elevations in 62%, values &#x0003e;5 times ULN in 16% [some on therapy], hepatitis with jaundice in 8%; 2 patients developed acute liver failure and one died, the rest recovered without residual injury).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.lachmann.2009.2416">Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, et al. Canakinumab in CAPS Study Group.  Use of canakinumab in the cryopyrin-associated periodic syndrome. <span><span class="ref-journal">N Engl J Med. </span>2009;<span class="ref-vol">360</span>:2416–25.</span> [<a href="/pubmed/19494217" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19494217</span></a>]<div><i>(Among 35 patients with CAPS from 11 centers in 5 countries treated with either canakinumab or placebo in various regimens, 34 of 35 receiving canakinumab had a clinical remission which was maintained in those who continued drug; ALT elevations [&#x0003e;5 times ULN] occurred in 1 treated patient [3%]).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.furst.2010.327">Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. <span><span class="ref-journal">Semin Arthritis Rheum. </span>2010;<span class="ref-vol">39</span>:327–46.</span> [<a href="/pubmed/19117595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19117595</span></a>]<div><i>(Review of the excess risk of infections during biologic therapy of rheumatoid arthritis mentions that the rate of infections was 2.1% in anakinra treated patients vs 0.4% in controls; infections were primarily pneumonia and skin infections, none were fatal and few were opportunistic infections).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.so.2010.3064">So A, De Meulemeester M, Pikhlak A, Y&#x000fc;cel AE, Richard D, Murphy V, Arulmani U, et al.  Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. <span><span class="ref-journal">Arthritis Rheum. </span>2010;<span class="ref-vol">62</span>:3064–76.</span> [<a href="/pubmed/20533546" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20533546</span></a>]<div><i>(Among 200 patients with an attack of acute gouty arthritis, ALT elevations occurred in 2 of 143 patients [1.4%] given a single dose of canakinumab, but in 0 of 57 [0%] given a single dose of triamcinolone).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.carroll.2011.533">Carroll MB. The impact of biologic response modifiers on hepatitis B virus infection. <span><span class="ref-journal">Expert Opin Biol Ther. </span>2011;<span class="ref-vol">11</span>:533–44.</span> [<a href="/pubmed/21269234" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21269234</span></a>]<div><i>(Review of reactivation of hepatitis B by biologic response modifiers; canakinumab has not been linked to reactivation of HBV, but experience with its use has been limited).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.kon_paut.2011.r202">Kon&#x000e9;-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Leslie KS, Mouy R, Ferreira A, et al. Canakinumab in CAPS Study Group.  Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. <span><span class="ref-journal">Arthritis Res Ther. </span>2011;<span class="ref-vol">13</span>:R202.</span> [<a href="/pmc/articles/PMC3334655/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3334655</span></a>] [<a href="/pubmed/22152723" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22152723</span></a>]<div><i>(Further follow up on 31 patients with CAPS treated with canakinumab [Lachmann 2009] focusing upon quality of life; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.kuemmerledeschner.2011.2095">Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, Hoyer J, et al.  Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. <span><span class="ref-journal">Ann Rheum Dis. </span>2011;<span class="ref-vol">70</span>:2095–102.</span> [<a href="/pubmed/21859692" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21859692</span></a>]<div><i>(Open label study of canakinumab [every 8 weeks for up to 2 years] in 166 patients with CAPS; predominant adverse effects were infections [66%]; "biochemistry evaluations at the end of the study showed no clinically significant changes from baseline").</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.rubbertroth.2012.v38">Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. <span><span class="ref-journal">Rheumatology (Oxford). </span>2012;<span class="ref-vol">51</span> Suppl 5:v38–47.</span> [<a href="/pubmed/22718926" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22718926</span></a>]<div><i>(Overview of safety of biologic agents in rheumatoid arthritis discusses anakinra, but not canakinumab).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF14">Drugs for rheumatoid arthritis. <span><span class="ref-journal">Treat Guidel Med Lett. </span>2012;<span class="ref-vol">10</span>(117):37–44.</span> [<a href="/pubmed/22538522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22538522</span></a>]<div><i>(Concise summary on current therapies of rheumatoid arthritis discusses anakinra and tocilizumab, but not canakinumab).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.ruperto.2012.2396">Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, et al.  PRINTO; PRCSG. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. <span><span class="ref-journal">N Engl J Med. </span>2012;<span class="ref-vol">367</span>:2396–406.</span> [<a href="/pubmed/23252526" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23252526</span></a>]<div><i>(Among 177 patents with systemic juvenile arthritis treated with canakinumab [4 mg/kg] every 8 weeks for 12 to 32 weeks, the major adverse effects were infections [55%]; although median values for ALT and AST did not change during therapy, values ranged from 5-82 U/L before therapy and were 7-828 at the end of 29 days and 0-282 U/L at the end of an open label phase [12-32 weeks]).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.sandborg.2012.2439">Sandborg C, Mellins ED. A new era in the treatment of systemic juvenile idiopathic arthritis. <span><span class="ref-journal">N Engl J Med. </span>2012;<span class="ref-vol">367</span>:2439–40.</span> [<a href="/pubmed/23252530" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23252530</span></a>]<div><i>(Editorial in response to Ruperto [2012] and De Benedetti [2012] on IL-1 antagonists as therapy of juvenile idiopathic arthritis; "the therapeutic benefits of these biologic agents will need to be weighed against the apparent risks of infection, neutropenia and liver dysfunction").</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.dinarello.2012.633">Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. <span><span class="ref-journal">Nat Rev Drug Discov. </span>2012;<span class="ref-vol">11</span>:633–52.</span> [<a href="/pmc/articles/PMC3644509/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3644509</span></a>] [<a href="/pubmed/22850787" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22850787</span></a>]<div><i>(Review of the biologic actions of IL-1 and the clinical efficacy and safety of agents that block its activity including anakinra [IL-1Ra], canakinumab [monoclonal antibody to IL-1 beta] and rilonacept [recombinant soluble IL-1 receptor]).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.brizi.2012.907">Brizi MG, Galeazzi M, Lucherini OM, Cantarini L, Cimaz R. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. <span><span class="ref-journal">Ann Intern Med. </span>2012;<span class="ref-vol">156</span>:907–8.</span> [<a href="/pubmed/22711098" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22711098</span></a>]<div><i>(35 year old woman with TRAPS had a beneficial response to course of canakinumab; no mention of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.schlesinger.2012.1839">Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, Krammer G, et al.  Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. <span><span class="ref-journal">Ann Rheum Dis. </span>2012;<span class="ref-vol">71</span>:1839–48.</span> [<a href="/pubmed/22586173" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22586173</span></a>]<div><i>(Controlled trial of single dose of canakinumab in patients with an attack of acute gouty arthritis; ALT elevations [&#x0003e;3 times ULN] occurred in 4 of 225 [2%] treated with canakinumab vs 7 of 229 [3%] given triamcinolone).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.kontzias.2012.201">Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL-1&#x003b2; long-acting inhibitor, in refractory adult-onset Still's disease. <span><span class="ref-journal">Semin Arthritis Rheum. </span>2012;<span class="ref-vol">42</span>:201–5.</span> [<a href="/pubmed/22512815" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22512815</span></a>]<div><i>(38 year old man and 36 year old woman with adult onset Still disease who were resistant to treatment with prednisone, methotrexate and anakinra had a complete and maintained response to canakinumab; no mention of side effects or ALT levels on treatment).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.miyamae.2012.109">Miyamae T. Cryopyrin-associated periodic syndromes: diagnosis and management. <span><span class="ref-journal">Paediatr Drugs. </span>2012;<span class="ref-vol">14</span>:109–17.</span> [<a href="/pubmed/22335455" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22335455</span></a>]<div><i>(Review of the clinical features, pathogenesis and therapy of CAPS with specific discussion of anakinra, rilonacept and canakinumab; no mention of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.ruperto.2012.557">Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, Bader-Meunier B, et al. Paediatric Rheumatology International Clinical Trials Organisation.  A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. <span><span class="ref-journal">Arthritis Rheum. </span>2012;<span class="ref-vol">64</span>:557–67.</span> [<a href="/pubmed/21953497" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21953497</span></a>]<div><i>(Open label, dose escalation study of canakinumab in 23 children with juvenile idiopathic arthritis treated for up to 6 months; "There were no clinically relevant changes in the laboratory findings").</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.vanderschueren.2013.413">Vanderschueren S, Knockaert D. Canakinumab in Schnitzler syndrome. <span><span class="ref-journal">Semin Arthritis Rheum. </span>2013;<span class="ref-vol">42</span>:413–6.</span> [<a href="/pubmed/22901459" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22901459</span></a>]<div><i>(37 year old man with Schnitzler syndrome resistant to other therapies [including anakinra] had an immediate and sustained response to canakinumab; "chemistry laboratory values were monitored and no abnormalities were observed").</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.moran.2013.1905">Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, et al.  Type 1 Diabetes TrialNet Canakinumab Study Group; AIDA Study Group. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. <span><span class="ref-journal">Lancet. </span>2013;<span class="ref-vol">381</span>(9881):1905–15.</span> [<a href="/pmc/articles/PMC3827771/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3827771</span></a>] [<a href="/pubmed/23562090" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23562090</span></a>]<div><i>(Two parallel trials comparing anakinra or canakinumab to placebo is 69 patients with recent onset of type 1 diabetes found no evidence of benefit and similar side effects of both drugs; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.akgul.2013.137">Akgul O, Kilic E, Kilic G, Ozgocmen S. Efficacy and safety of biologic treatments in familial Mediterranean fever. <span><span class="ref-journal">Am J Med Sci. </span>2013;<span class="ref-vol">346</span>:137–41.</span> [<a href="/pubmed/23276893" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23276893</span></a>]<div><i>(Systematic review of reports on biologic response modifiers in familial Mediterranean fever identified no controlled trials, but 24 single reports and 7 case series describing 59 patients, 35 on anti-TNF agents, 29 anakinra, 4 canakinumab; 2 had adverse events that required stopping, but the rest seemed to have a beneficial effect; no discussion of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF26">Canakinumab (Ilaris) for systemic juvenile idiopathic arthritis. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2013;<span class="ref-vol">55</span>(1423):65–6.</span> [<a href="/pubmed/23959387" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23959387</span></a>]<div><i>(Concise review of the pharmacology, mechanism of action, efficacy and safety of canakinumab shortly after its approval for juvenile idiopathic arthritis in the US; mentions that neutropenia, thrombocytopenia and elevated aminotransferases have been reported with its use).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.banse.2013.653">Banse C, Vittecoq O, Benhamou Y, Gauthier-Prieur M, Lequerr&#x000e9; T, L&#x000e9;vesque H. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease. <span><span class="ref-journal">Joint Bone Spine. </span>2013;<span class="ref-vol">80</span>:653–5.</span> [<a href="/pubmed/23751410" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23751410</span></a>]<div><i>(49 year old woman with Still disease developed suspected macrophage activation syndrome after a second infusion of canakinumab with high fever, abdominal pain and hepatomegaly [bilirubin not given, ALT 20 times ULN], resolving with high dose glucocorticoid therapy).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.wulffraat.2015.1961">Wulffraat NM. A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis. <span><span class="ref-journal">Expert Opin Drug Saf. </span>2015;<span class="ref-vol">14</span>:1961–7.</span> [<a href="/pubmed/26568054" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26568054</span></a>]<div><i>(Systematic review of the adverse events associated with canakinumab therapy focuses on common events such as abdominal pain, injection site reactions and infections and the more serious events such as septicemia and macrophage activation syndrome; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.krause.2017.1311">Krause K, Tsianakas A, Wagner N, Fischer J, Weller K, Metz M, Church MK, et al.  Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2017;<span class="ref-vol">139</span>:1311–20.</span> [<a href="/pubmed/27658762" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27658762</span></a>]<div><i>(Among 20 patients with Schnitzler syndrome treated with canakinumab or placebo for 7 days followed by open label therapy, canakinumab was associated with marked clinical improvements in most patients and "no significant changes in safety laboratory parameters were observed").</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.tarp.2016.669">Tarp S, Amarilyo G, Foeldvari I, Christensen R, Woo JM, Cohen N, Pope TD, et al.  Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. <span><span class="ref-journal">Rheumatology (Oxford). </span>2016;<span class="ref-vol">55</span>:669–79.</span> [<a href="/pmc/articles/PMC5854101/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5854101</span></a>] [<a href="/pubmed/26628580" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26628580</span></a>]<div><i>(Systematic review of the literature of the safety of biologic agents for juvenile idiopathic arthritis mentions that serious adverse events including infections were no more frequent with canakinumab than placebo therapy; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.lenert.2016.711">Lenert A, Yao Q. Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature. <span><span class="ref-journal">Semin Arthritis Rheum. </span>2016;<span class="ref-vol">45</span>:711–6.</span> [<a href="/pubmed/26672682" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26672682</span></a>]<div><i>(Description of 7 patients with adult onset Still&#x02019;s disease who developed macrophage activation syndrome soon after initial presentation manifested by fever, rash, arthralgias, lymphopenia, leukocytosis and liver test abnormalities [mean bilirubin 4.2 mg/dL, ALT 290 U/L, LDH 2167 U/L, INR 1.58] and variable degrees of renal and pulmonary failure and hemophagocytosis present in 3 of 7 bone marrow biopsies, with excellent response to anakinra).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.colafrancesco.2017.369">Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E, Cammelli D, et al.  Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still's disease: a multicentre retrospective observational study. <span><span class="ref-journal">Front Pharmacol. </span>2017;<span class="ref-vol">8</span>:369.</span> [<a href="/pmc/articles/PMC5469286/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5469286</span></a>] [<a href="/pubmed/28659802" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28659802</span></a>]<div><i>(Among 140 patients with adult onset Still&#x02019;s disease followed at 18 Italian referral centers treated with anakinra, clinical responses were common and the most frequent adverse events were local injection reactions, rash and infections [15%] while hepatomegaly and liver test abnormalities decreased on treatment (from 47% to 5%]; therapy was switched to canakinumab in 4 patients with an unsatisfactory response to anakinra and 3 responded and &#x0201c;no adverse events were registered&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.arostegui.2017.1679">Arostegui JI, Anton J, Calvo I, Robles A, Iglesias E, L&#x000f3;pez-Montesinos B, Banchereau R, et al.  Open-label, phase II study to assess the efficacy and safety of canakinumab treatment in active hyperimmunoglobulinemia D with periodic fever syndrome. <span><span class="ref-journal">Arthritis Rheumatol. </span>2017;<span class="ref-vol">69</span>:1679–88.</span> [<a href="/pubmed/28482144" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28482144</span></a>]<div><i>(Among 9 patients with hyperimmunoglobulin D syndrome with periodic fever treated with canakinumab for 6 months, all achieved a complete clinical response, and 7 of the 9 relapsed on withdrawal; adverse events included infections and transient ALT elevations in two patients).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.ruperto.2018.1710">Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, Kasapcopur O, et al. Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).  Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. <span><span class="ref-journal">Ann Rheum Dis. </span>2018;<span class="ref-vol">77</span>:1710–9.</span> [<a href="/pmc/articles/PMC6241618/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6241618</span></a>] [<a href="/pubmed/30269054" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30269054</span></a>]<div><i>(Among 144 children with juvenile idiopathic arthritis enrolled in controlled trials [Ruperto 2012] who were continued on therapy in extension studies, 102 discontinued treatment because of lack of efficacy while clinical efficacy was maintained in the rest, adverse events included macrophage activation syndrome [6%], hepatitis [1%] and hepatic enzyme elevations [2%]).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.feist.2018.668">Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, Cantarini L, et al.  Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. <span><span class="ref-journal">Clin Exp Rheumatol. </span>2018;<span class="ref-vol">36</span>:668–75.</span> [<a href="/pubmed/29533755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29533755</span></a>]<div><i>(Pooled analysis of results of canakinumab therapy in 4 clinical trials including 301 patients with juvenile idiopathic arthritis found similar rates of efficacy and adverse events among age groups [0-11 vs 12-15 vs 16-20], macrophage activation syndrome occurring in 22 [7.3%], hepatitis in 4 [1.3%] and liver enzyme elevations in 5 [1.7%]).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.sota.2018.2233">Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M, et al.  &#x0201c;Working Group&#x0201d; of Systemic Autoinflammatory Diseases of SIR (Italian Society of Rheumatology). Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. <span><span class="ref-journal">Clin Rheumatol. </span>2018;<span class="ref-vol">37</span>:2233–40.</span> [<a href="/pubmed/29770930" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29770930</span></a>]<div><i>(Among 475 patients treated with anakinra or canakinumab for various inflammatory conditions for an average of 24 months, the most frequently reported adverse events were rash, injection site reactions, infections, cytopenias, and anaphylaxis; one patient developed serum enzyme elevations and one macrophage activation syndrome).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.giacomelli.2018.24">Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still's disease. <span><span class="ref-journal">J Autoimmun. </span>2018;<span class="ref-vol">93</span>:24–36.</span> [<a href="/pubmed/30077425" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30077425</span></a>]<div><i>(Review of the pathogenesis, clinical features, complications and therapy of adult onset Still&#x02019;s disease mentions that liver test abnormalities have been reported in 37-74% of subjects and that anakinra has been studied in at least 13 small open label trials with response rates of 46-100% and both canakinumab or rilonacept have been found to be helpful in cases with intolerance or an inadequate response to anakinra).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.crayne.2019.119">Crayne CB, Albeituni S, Nichols KE, Cron RQ. The Immunology of macrophage activation syndrome. <span><span class="ref-journal">Front Immunol. </span>2019;<span class="ref-vol">10</span>:119.</span> [<a href="/pmc/articles/PMC6367262/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6367262</span></a>] [<a href="/pubmed/30774631" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30774631</span></a>]<div><i>(Review of the immunopathogenesis of the macrophage activation syndrome, a complication of several systemic inflammatory disorders including juvenile idiopathic arthritis, systemic lupus erythematosus and adult onset Still&#x02019;s disease, characterized by high circulating levels of proinflammatory cytokines which has led to the experimental use of cytokine inhibitors such as anakinra or canakinumab).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.brogan.2019.1955">Brogan PA, Hofer M, Kuemmerle-Deschner JB, Kon&#x000e9;-Paut I, Roesler J, Kallinich T, Horneff G, et al.  Rapid and sustained long-term efficacy and safety of canakinumab in patients With cryopyrin-associated periodic syndrome ages five years and younger. <span><span class="ref-journal">Arthritis Rheumatol. </span>2019;<span class="ref-vol">71</span>:1955–63.</span> [<a href="/pmc/articles/PMC6899890/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6899890</span></a>] [<a href="/pubmed/31161734" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31161734</span></a>]<div><i>(Among 17 children less than 5 years of age with a cryopyrin-associated periodic syndrome treated with canakinumab, all had a complete clinical response and adverse events included diarrhea, pneumonia, rhinitis, fever and cough but none led to discontinuation; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Canakinumab.REF.sfriso.2020.129">Sfriso P, Bindoli S, Doria A, Feist E, Galozzi P. Canakinumab for the treatment of adult-onset Still's disease. <span><span class="ref-journal">Expert Rev Clin Immunol. </span>2020;<span class="ref-vol">16</span>:129–38.</span> [<a href="/pubmed/31957508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31957508</span></a>]<div><i>(Review of the clinical efficacy and safety of canakinumab for adult-onset Still&#x02019;s disease for which it is not approved in the US, despite evidence for its efficacy in small case series and clinical trials; the most concerning adverse events reported with canakinumab were diarrhea and macrophage activation syndrome; no mention of ALT elevations or hepatotoxicity).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK547883</span><span class="label">PMID: <a href="/pubmed/31643219" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643219</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/CalciumChannelBlocke/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Candesartan/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK547883&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK547883/?report=reader">PubReader</a></li><li><a href="/books/NBK547883/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK547883" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK547883" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Canakinumab. [Updated 2020 Apr 20].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK547883/pdf/Bookshelf_NBK547883.pdf">PDF version of this page</a> (119K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Canakinumab+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Canakinumab: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Canakinumab" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Canakinumab: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4856910" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4856910" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27367267" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.</a><span class="source">[Expert Rev Clin Pharmacol. 2016]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Orrock JE, Ilowite NT. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Expert Rev Clin Pharmacol. 2016 Aug; 9(8):1015-24. Epub 2016 Jul 6.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26284424" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.</a><span class="source">[MAbs. 2015]</span><div class="brieflinkpop offscreen_noflow">The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Rondeau JM, Ramage P, Zurini M, Gram H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">MAbs. 2015; 7(6):1151-60. Epub 2015 Aug 18.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27790042" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Treatment of systemic-onset juvenile arthritis with canakinumab.</a><span class="source">[Open Access Rheumatol. 2015]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Treatment of systemic-onset juvenile arthritis with canakinumab.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Peitz J, Horneff G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Open Access Rheumatol. 2015; 7:23-31. Epub 2015 Feb 18.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27119439" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis.</a><span class="source">[J Clin Pharmacol. 2016]</span><div class="brieflinkpop offscreen_noflow">Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sun H, Van LM, Floch D, Jiang X, Klein UR, Abrams K, Sunkara G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Clin Pharmacol. 2016 Dec; 56(12):1516-1527. Epub 2016 Jun 8.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25269376" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Canakinumab for the treatment of systemic juvenile idiopathic arthritis.</a><span class="source">[Expert Rev Clin Immunol. 2014]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Canakinumab for the treatment of systemic juvenile idiopathic arthritis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Grom AA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Expert Rev Clin Immunol. 2014 Nov; 10(11):1427-35. Epub 2014 Oct 1.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643219" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643219" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="&#10;                        HTOn&#10;                    "><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:28:11-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal106&amp;ncbi_phid=CE8D18F0046640110000000005080171&amp;ncbi_session=CE8D18F00467ACA1_1288SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK547883%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK547883&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK547883/&amp;ncbi_pagename=Canakinumab - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D18F00467ACA1_1288SID /projects/books/PBooks@9.2 portal106 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>